EGFR+ Lung Cancer

Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>at the 19^thAnnual International Lung Cancer Congress, Bunn, professor in the Division of Medical Oncology at the University of Colorado Cancer Center, discussed the potential approaches with neoadjuvant or adjuvant therapies for curing patients with lung cancer. He also shares his own opinions on which approaches might be best.

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.

In a keynote address by Frances A. Shepherd, MD, FRCPC, OOnt, OC, during the&nbsp;<em>19th Annual </em>International Lung Cancer Congress, Shepherd expressed that <em>EGFR-</em>mutant non&ndash;small cell lung cancer (NSCLC) is a model for how far the field of lung cancer has progressed in the past decade, thanks in large part to molecular pathologists.&nbsp;

Several biomarkers are beginning to emerge for immunotherapy in non&ndash;small cell lung cancer, and the collection of these markers, when used together, could further help to predict which patients are likely to respond to these therapies alone or in combination, according to a presentation by Giorgio Scagliotti, MD, PhD, at the <em>19th Annual</em> International Lung Cancer Congress.

Several novel agents are beginning to show promise for new targets in non&ndash;small cell lung cancer, especially <em>NRG1</em> and <em>LKB1,&nbsp;</em>and could be positioned to join&nbsp;already established standard-of-care therapies.

The primary endpoint of the phase III ALTA-1L trial has been met, as brigatinib was found to reduce the risk of&nbsp;disease progression or death versus crizotinib in adult patients with locally advanced or metastatic <em>ALK</em>-positive non&ndash;small cell lung cancer who had not received a prior ALK inhibitor,&nbsp;Takeda Pharmaceutical Company, the manufacturer of brigatinib, has announced.

According to findings from the&nbsp;phase III IMpower132 study, the addition of atezolizumab to pemetrexed and cisplatin or carboplatin reduced the risk of disease progression or death compared with chemotherapy alone in patients with&nbsp;advanced nonsquamous non&ndash;small cell lung cancer.

Alexander Drilon, MD, discusses the data currently available with targeting gene fusions, and shares insight into what is on the horizon in this area.

Clinical Management of NSCLC With Bone Metastases

Managing Metastatic NSCLC With Rapid Progression

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.